Spyryx Biosciences to Present at American Thoracic Society International Conference May 19- 24, 2017, Washington, DC

DURHAM, N.C., May 16, 2017 /PRNewswire/ -- Spyryx Biosciences, Inc., a clinical-stage biopharmaceutical company developing innovative therapeutics to address severe lung diseases, today announced that it will present two abstracts highlighting the safety, pharmacokinetics and mechanism of action of SPX-101, the Company's pipeline therapeutic treatment for cystic fibrosis (CF).

SPX-101 is an inhaled peptide with a novel mechanism for regulating epithelial sodium channel density in the airway.  The drug is designed to restore a cellular pathway in the lung that promotes airway hydration and mucociliary clearance, which are dysfunctional in CF. The mechanism of action of SPX-101 is independent of the genetic mutations that cause CF, which makes it a potential therapy for all CF patients.

Posters to be presented:

Poster # 114 
A4736 "Safety and Pharmacokinetics of SPX-101 in Healthy Human Subjects"

Monday, May, 22, 2017 
2:15 PM – 4:15 PM 
Room 144 A-C 
Walter E. Washington Convention Center

Poster # P105 
A7674 "SPX-101 Is a Novel ENaC-Targeted Therapeutic for Cystic Fibrosis that Restores Mucus Transport"

Tuesday, May 23, 2017 
11:15 AM – 1:00 PM 
Area B, Hall B-C 
Walter E. Washington Convention Center

About Cystic Fibrosis 
CF is an autosomal recessive genetic disorder affecting approximately 75,000 individuals worldwide.  The disease is caused by mutations in the gene for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. CF profoundly affects the lungs and respiratory tract and is characterized by dehydration of the airway surface, resulting in reduced mucus clearance, the lung's principle mechanism for maintaining a clean environment. The mucus becomes thick and sticky, progressively accumulating into obstructions that block airflow and result in recurrent colonization of the airways by viruses and bacteria.  These pathogens lead to frequent, acute lung infections, chronic inflammation, exacerbations, and impaired lung function. The long-term result of the disease is progressive, permanent tissue damage and scarring (fibrosis) in the lung.  No cure for cystic fibrosis is known, although several treatments have been approved to address the underlying cause of the disease in some patients. Despite currently available treatment, the median age of survival for CF patients is approximately 40 years of age.

About Spyryx Biosciences 
Spyryx Biosciences is a privately held, clinical-stage biopharmaceutical company developing innovative therapeutics to address severe lung diseases. Spyryx's lead clinical candidate, SPX-101, is a novel treatment for cystic fibrosis that has successfully completed a Phase 1 study in healthy volunteers and is advancing into Phase 2 in CF patients. The product has demonstrated a robust ability to restore mucociliary clearance in animal models of the disease and has the potential to improve lung function in all cystic fibrosis patients independent of their CFTR mutation. The Spyryx leadership team and scientific staff have extensive experience in the development of respiratory medicines and work closely with a broad group of clinical and scientific experts in the pulmonary field. Spyryx is funded by a first tier syndicate of life science investors, including Canaan Partners, 5AM Ventures and Hatteras Venture Partners. Further information regarding Spyryx Biosciences is available at www.spyryxbio.com.

SOURCE Spyryx Biosciences

Related Links

http://www.spyryxbio.com